A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers

Trial Profile

A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Obiltoxaximab (Primary)
  • Indications Anthrax
  • Focus Adverse reactions; Registrational
  • Sponsors EluSys Therapeutics
  • Most Recent Events

    • 30 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Apr 2014 Planned number of patients changed from 20 to 36 as reported by ClinicalTrials.gov
    • 10 Apr 2014 Planned End Date changed from 1 Oct 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top